Attacking the multi-tiered proteolytic pathology of COPD: New insights from basic and translational studies

Pharmacology and Therapeutics

Volumn 121, Issue 2, 2009, Pages 132-146

  Djekic, Uros V ^a   Gaggar, Amit ^a,b   Weathington, Nathaniel M ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Collagenase; COPD; Elastase; Extracellular matrix; Inflammation; MMP inhibitor; Prolyl endopeptidase

Indexed keywords

COLLAGEN; CYTOKINE; ELASTIN; PROTEINASE;

CHEMOTAXIS; CHRONIC DISEASE; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOKINE PRODUCTION; DISEASE COURSE; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW;

ANIMALS; CHEMOTAXIS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; EXTRACELLULAR MATRIX; HUMANS; PEPTIDE HYDROLASES; PROTEASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 59849113942     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2008.09.008     Document Type: Review

References (192)

1. From the global strategy for the diagnosis, management and prevention of COPD, global initiative for chronic obstructive lung disease (gold), (2007).
2. Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach, (2007). In J. B. A. Nikolai & Khaltaev (Eds.).
3. Aoshiba K., Nagai A., and Konno K. Erythromycin shortens neutrophil survival by accelerating apoptosis. Antimicrob Agents Chemother 39 4 (1995) 872-877
4. Aoyagi T., Wada T., Daskalov H.P., Kojima F., Nagai M., Harada S., et al. Dissociation between serine proteinases and proline related enzymes in spleen of MRL mouse as a model of systemic lupus erythematodes. Biochem Int 14 3 (1987) 435-441
5. Aoyagi T., Wada T., Ishikawa Y., Kojima F., Nagai M., Osanai T., et al. Systemic enzymatic changes in guinea pigs suffering from experimental allergic encephalomyelitis. J Pharmacobiodyn 6 12 (1983) 963-973
6. Aoyagi T., Wada T., Kojima F., Nagai M., Okubo M., Masaki Y., et al. Abnormality of the post-proline-cleaving enzyme activity in mice with systemic lupus erythematosus-like syndrome. J Appl Biochem 7 4-5 (1985) 273-281
7. Atack J.R., Suman-Chauhan N., Dawson G., and Kulagowski J.J. In vitro and in vivo inhibition of prolyl endopeptidase. Eur J Pharmacol 205 2 (1991) 157-163
8. Attucci S., Gauthier A., Korkmaz B., Delepine P., Martino M.F., Saudubray F., et al. Epi-hne4, a proteolysis-resistant inhibitor of human neutrophil elastase and potential anti-inflammatory drug for treating cystic fibrosis. J Pharmacol Exp Ther 318 2 (2006) 803-809
9. Bakker A.V., Jung S., Spencer R.W., Vinick F.J., and Faraci W.S. Slow tight-binding inhibition of prolyl endopeptidase by benzyloxycarbonyl-prolyl-prolinal. Biochem J 271 2 (1990) 559-562
10. Barelli H., Petit A., Hirsch E., Wilk S., De Nanteuil G., Morain P., et al. S 17092-1, a highly potent, specific and cell permeant inhibitor of human proline endopeptidase. Biochem Biophys Res Commun 257 3 (1999) 657-661
11. Barnes P.J. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 8 3 (2008) 183-192
12. Barnes P.J., Shapiro S.D., and Pauwels R.A. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 22 4 (2003) 672-688
13. Barrett A.J., and Rawlings N.D. Oligopeptidases, and the emergence of the prolyl oligopeptidase family. Biol Chem Hoppe Seyler 373 7 (1992) 353-360
14. Beeh K.M., Beier J., Kornmann O., and Buhl R. Sputum matrix metalloproteinase-9, tissue inhibitor of metalloprotinease-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. Respir Med 97 6 (2003) 634-639
15. Beeh K.M., Beier J., Kornmann O., Micke P., and Buhl R. Sputum levels of metalloproteinase-9 and tissue inhibitor of metalloproteinase-1, and their ratio correlate with airway obstruction in lung transplant recipients: relation to tumor necrosis factor-alpha and interleukin-10. J Heart Lung Transplant 20 11 (2001) 1144-1151
16. Bellemere G., Morain P., Vaudry H., and Jegou S. Effect of S 17092, a novel prolyl endopeptidase inhibitor, on substance p and alpha-melanocyte-stimulating hormone breakdown in the rat brain. J Neurochem 84 5 (2003) 919-929
17. Bellemere G., Vaudry H., Morain P., and Jegou S. Effect of prolyl endopeptidase inhibition on arginine-vasopressin and thyrotrophin-releasing hormone catabolism in the rat brain. J Neuroendocrinol 17 5 (2005) 306-313
18. Betsuyaku T., Nishimura M., Takeyabu K., Tanino M., Miyamoto K., and Kawakami Y. Decline in FEV(1) in community-based older volunteers with higher levels of neutrophil elastase in bronchoalveolar lavage fluid. Respiration 67 3 (2000) 261-267
19. Betsuyaku T., Nishimura M., Takeyabu K., Tanino M., Venge P., Xu S., et al. Neutrophil granule proteins in bronchoalveolar lavage fluid from subjects with subclinical emphysema. Am J Respir Crit Care Med 159 6 (1999) 1985-1991
20. Bornstein P. The biosynthesis of collagen. Annu Rev Biochem 43 (1974) 567-603
21. Boyle J.R., McDermott E., Crowther M., Wills A.D., Bell P.R., and Thompson M.M. Doxycycline inhibits elastin degradation and reduces metalloproteinase activity in a model of aneurysmal disease. J Vasc Surg 27 2 (1998) 354-361
22. Bradbury J. Neutrophil elastase inhibitors for cystic fibrosis. Drug Discov Today 6 9 (2001) 441-442
23. Brenner S. The molecular evolution of genes and proteins: a tale of two serines. Nature 334 6182 (1988) 528-530
24. Camargo A.C., Caldo H., and Reis M.L. Susceptibility of a peptide derived from bradykinin to hydrolysis by brain endo-oligopeptidases and pancreatic proteinases. J Biol Chem 254 12 (1979) 5304-5307
25. Carvalho K.M., and Camargo A.C. Purification of rabbit brain endooligopeptidases and preparation of anti-enzyme antibodies. Biochemistry 20 25 (1981) 7082-7088
26. Churg A., and Wright J.L. Proteases and emphysema. Curr Opin Pulm Med 11 2 (2005) 153-159
27. Churg A., Zay K., Shay S., Xie C., Shapiro S.D., Hendricks R., et al. Acute cigarette smoke-induced connective tissue breakdown requires both neutrophils and macrophage metalloelastase in mice. Am J Respir Cell Mol Biol 27 3 (2002) 368-374
28. Corbel M., Theret N., Caulet-Maugendre S., Germain N., Lagente V., Clement B., et al. Repeated endotoxin exposure induces interstitial fibrosis associated with enhanced gelatinase (MMP-2 and MMP-9) activity. Inflamm Res 50 3 (2001) 129-135
29. Crystal R.G. The Lung: Scientific Foundations. 2nd ed. (1997), Lippincott-Raven, Philadelphia
30. Culpitt S.V., Maziak W., Loukidis S., Nightingale J.A., Matthews J.L., and Barnes P.J. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160 5 Pt 1 (1999) 1635-1639
31. Cunningham D.F., and O'Connor B. Proline specific peptidases. Biochim Biophys Acta 1343 2 (1997) 160-186
32. D'Armiento J., Dalal S.S., Okada Y., Berg R.A., and Chada K. Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema. Cell 71 6 (1992) 955-961
33. Deshmukh H.S., Case L.M., Wesselkamper S.C., Borchers M.T., Martin L.D., Shertzer H.G., et al. Metalloproteinases mediate mucin 5ac expression by epidermal growth factor receptor activation. Am J Respir Crit Care Med 171 4 (2005) 305-314
34. Dirksen A., Dijkman J.H., Madsen F., Stoel B., Hutchison D.C., Ulrik C.S., et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 160 5 Pt 1 (1999) 1468-1472
35. Dunsmore S.E., Saarialho-Kere U.K., Roby J.D., Wilson C.L., Matrisian L.M., Welgus H.G., et al. Matrilysin expression and function in airway epithelium. J Clin Invest 102 7 (1998) 1321-1331
36. Duranton J., and Bieth J.G. Inhibition of proteinase 3 by [alpha]1-antitrypsin in vitro predicts very fast inhibition in vivo. Am J Respir Cell Mol Biol 29 1 (2003) 57-61
37. Elewski B.E., Lamb B.A., Sams Jr. W.M., and Gammon W.R. In vivo suppression of neutrophil chemotaxis by systemically and topically administered tetracycline. J Am Acad Dermatol 8 6 (1983) 807-812
38. Emingil G., Atilla G., Sorsa T., Luoto H., Kirilmaz L., and Baylas H. The effect of adjunctive low-dose doxycycline therapy on clinical parameters and gingival crevicular fluid matrix metalloproteinase-8 levels in chronic periodontitis. J Periodontol 75 1 (2004) 106-115
39. Endo S., Sato N., Yaegashi Y., Suzuki Y., Kojika M., Yamada Y., et al. Sivelestat sodium hydrate improves septic acute lung injury by reducing alveolar dysfunction. Res Commun Mol Pathol Pharmacol 119 1-6 (2006) 53-65
40. Equi A., Balfour-Lynn I.M., Bush A., and Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 360 9338 (2002) 978-984
41. Faurschou M., and Borregaard N. Neutrophil granules and secretory vesicles in inflammation. Microbes Infect 5 14 (2003) 1317-1327
42. Fingleton B. Mmps as therapeutic targets-still a viable option?. Semin Cell Dev Biol 19 1 (2008) 61-68
43. Finlay G.A., O'Driscoll L.R., Russell K.J., D'Arcy E.M., Masterson J.B., FitzGerald M.X., et al. Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am J Respir Crit Care Med 156 1 (1997) 240-247
44. Finlay G.A., Russell K.J., McMahon K.J., D'Arcy E.M., Masterson J.B., FitzGerald M.X., et al. Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. Thorax 52 6 (1997) 502-506
45. Foronjy R.F., Okada Y., Cole R., and D'Armiento J. Progressive adult-onset emphysema in transgenic mice expressing human MMP-1 in the lung. Am J Physiol Lung Cell Mol Physiol 284 5 (2003) L727-737
46. Fukuoka Y., Hagihara M., Nagatsu T., and Kaneda T. The relationship between collagen metabolism and temporomandibular joint osteoarthrosis in mice. J Oral Maxillofac Surg 51 3 (1993) 288-291
47. Fulop V., Szeltner Z., Renner V., and Polgar L. Structures of prolyl oligopeptidase substrate/inhibitor complexes. use of inhibitor binding for titration of the catalytic histidine residue. J Biol Chem 276 2 (2001) 1262-1266
48. Gaggar A., Jackson P.L., Noerager B.D., O'Reilly P.J., McQuaid D.B., Rowe S.M., et al. A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J Immunol 180 8 (2008) 5662-5669
49. Gaggar A., Li Y., Weathington N., Winkler M., Kong M., Jackson P., et al. Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients. Am J Physiol Lung Cell Mol Physiol 293 1 (2007) L96-L104
50. Garcia-Horsman J.A., Mannisto P.T., and Venalainen J.I. On the role of prolyl oligopeptidase in health and disease. Neuropeptides 41 1 (2007) 1-24
51. Gass J., and Khosla C. Prolyl endopeptidases. Cell Mol Life Sci 64 3 (2007) 345-355
52. Geraghty P., Rogan M.P., Greene C.M., Boxio R.M., Poiriert T., O'Mahony M., et al. Neutrophil elastase up-regulates cathepsin b and matrix metalloprotease-2 expression. J Immunol 178 9 (2007) 5871-5878
53. Gerhardt S.G., McDyer J.F., Girgis R.E., Conte J.V., Yang S.C., and Orens J.B. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med 168 1 (2003) 121-125
54. Golub L.M., Lee H.M., Lehrer G., Nemiroff A., McNamara T.F., Kaplan R., et al. Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action. J Periodontal Res 18 5 (1983) 516-526
55. Golub L.M., Ramamurthy N.S., McNamara T.F., Greenwald R.A., and Rifkin B.R. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med 2 3 (1991) 297-321
56. Gomez D.E., Alonso D.F., Yoshiji H., and Thorgeirsson U.P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74 2 (1997) 111-122
57. Goossens F., De Meester I., Vanhoof G., and Scharpe S. A sensitive method for the assay of serum prolyl endopeptidase. Eur J Clin Chem Clin Biochem 30 4 (1992) 235-238
58. Goossens F., De Meester I., Vanhoof G., and Scharpe S. Distribution of prolyl oligopeptidase in human peripheral tissues and body fluids. Eur J Clin Chem Clin Biochem 34 1 (1996) 17-22
59. Goossens F.J., Wauters J.G., Vanhoof G.C., Bossuyt P.J., Schatteman K.A., Loens K., et al. Subregional mapping of the human lymphocyte prolyl oligopeptidase gene (PREP) to human chromosome 6q22. Cytogenet Cell Genet 74 1-2 (1996) 99-101
60. Gottlieb J., Elmer M., and Steiner R. Efficacy of intravenous ici-200,880, a neutrophil elastase inhibitor, in the treatment of adult respiratory distress syndrome. Chest 107 (1994) 67
61. Greenlee K.J., Werb Z., and Kheradmand F. Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted. Physiol Rev 87 1 (2007) 69-98
62. Guo G., Booms P., Halushka M., Dietz H.C., Ney A., Stricker S., et al. Induction of macrophage chemotaxis by aortic extracts of the mgr marfan mouse model and a GxxPG-containing fibrillin-1 fragment. Circulation 114 17 (2006) 1855-1862
63. Haddox J.L., Pfister R.R., Sommers C.I., Blalock J.E., and Villain M. Inhibitory effect of a complementary peptide on ulceration in the alkali-injured rabbit cornea. Invest Ophthalmol Vis Sci 42 12 (2001) 2769-2775
64. Hance K.A., Tataria M., Ziporin S.J., Lee J.K., and Thompson R.W. Monocyte chemotactic activity in human abdominal aortic aneurysms: role of elastin degradation peptides and the 67-kD cell surface elastin receptor. J Vasc Surg 35 2 (2002) 254-261
65. Hanemaaijer R., Visser H., Koolwijk P., Sorsa T., Salo T., Golub L.M., et al. Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells. Adv Dent Res 12 2 (1998) 114-118
66. Hartl D., Latzin P., Hordijk P., Marcos V., Rudolph C., Woischnik M., et al. Cleavage of cxcr1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat Med 13 12 (2007) 1423-1430
67. Harwood V.J., Denson J.D., Robinson-Bidle K.A., and Schreier H.J. Overexpression and characterization of a prolyl endopeptidase from the hyperthermophilic archaeon pyrococcus furiosus. J Bacteriol 179 11 (1997) 3613-3618
68. Harwood V.J., and Schreier H.J. Prolyl oligopeptidase from Pyrococcus furiosus. Methods Enzymol 330 (2001) 445-454
69. Hashimoto N., Kawabe T., Hara T., Imaizumi K., Wakayama H., Shimokata K., et al. Effects of erythromycin on matrix metalloproteinase-9(MMP-9)and cell migration. Jpn J Antibiot 54 Suppl A (2001) 137-138
70. Hautamaki R.D., Kobayashi D.K., Senior R.M., and Shapiro S.D. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 277 5334 (1997) 2002-2004
71. Hoshi K., Kurosawa S., Kaise A., Kato M., Andoh K., and Satoh D. Sivelestat, a neutrophil elastase inhibitor, reduces mortality rate of critically ill patients. Tohoku J Exp Med 207 2 (2005) 143-148
72. Houghton A.M., Quintero P.A., Perkins D.L., Kobayashi D.K., Kelley D.G., Marconcini L.A., et al. Elastin fragments drive disease progression in a murine model of emphysema. J Clin Invest 116 3 (2006) 753-759
73. Hoyt J.C., Ballering J., Numanami H., Hayden J.M., and Robbins R.A. Doxycycline modulates nitric oxide production in murine lung epithelial cells. J Immunol 176 1 (2006) 567-572
74. Hu J., Van den Steen P.E., Sang Q.X., and Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 6 6 (2007) 480-498
75. Jiang D., Liang J., Fan J., Yu S., Chen S., Luo Y., et al. Regulation of lung injury and repair by toll-like receptors and hyaluronan. Nat Med 11 11 (2005) 1173-1179
76. Johnson L.L., Dyer R., and Hupe D.J. Matrix metalloproteinases. Curr Opin Chem Biol 2 4 (1998) 466-471
77. Joos L., He J.Q., Shepherdson M.B., Connett J.E., Anthonisen N.R., Pare P.D., et al. The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. Hum Mol Genet 11 5 (2002) 569-576
78. Kadota J., Mukae H., Ishii H., Nagata T., Kaida H., Tomono K., et al. Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respir Med 97 7 (2003) 844-850
79. Kamori M., Hagihara M., Nagatsu T., Iwata H., and Miura T. Activities of dipeptidyl peptidase II, dipeptidyl peptidase iv, prolyl endopeptidase, and collagenase-like peptidase in synovial membrane from patients with rheumatoid arthritis and osteoarthritis. Biochem Med Metab Biol 45 2 (1991) 154-160
80. Kanai K., Asano K., Hisamitsu T., and Suzaki H. Suppression of matrix metalloproteinase-9 production from neutrophils by a macrolide antibiotic, roxithromycin, in vitro. Mediators Inflamm 13 5-6 (2004) 313-319
81. Kanai K., Asano K., Hisamitsu T., and Suzaki H. Suppression of matrix metalloproteinase production from nasal fibroblasts by macrolide antibiotics in vitro. Eur Respir J 23 5 (2004) 671-678
82. Kang T., Yi J., Guo A., Wang X., Overall C.M., Jiang W., et al. Subcellular distribution and cytokine- and chemokine-regulated secretion of leukolysin/MT6-MMP/MMP-25 in neutrophils. J Biol Chem 276 24 (2001) 21960-21968
83. Kao R.C., Wehner N.G., Skubitz K.M., Gray B.H., and Hoidal J.R. Proteinase 3. A distinct human polymorphonuclear leukocyte proteinase that produces emphysema in hamsters. J Clin Invest 82 6 (1988) 1963-1973
84. Kato T., Okada M., and Nagatsu T. Distribution of post-proline cleaving enzyme in human brain and the peripheral tissues. Mol Cell Biochem 32 3 (1980) 117-121
85. Katsube N., Sunaga K., Chuang D.M., and Ishitani R. ONO-1603, a potential antidementia drug, shows neuroprotective effects and increases m3-muscarinic receptor mRNA levels in differentiating rat cerebellar granule neurons. Neurosci Lett 214 2-3 (1996) 151-154
86. Kimura A., Yoshida I., Takagi N., and Takahashi T. Structure and localization of the mouse prolyl oligopeptidase gene. J Biol Chem 274 34 (1999) 24047-24053
87. Kobzik L. The lung. In: Cotrain V.K.R.S., and Collins T. (Eds). Robbins pathologic basis of disease (1999), W.B. Saunders Company, Philadelphia
88. Koida M., and Walter R. Post-proline cleaving enzyme. Purification of this endopeptidase by affinity chromatography. J Biol Chem 251 23 (1976) 7593-7599
89. Laskin D.L., Kimura T., Sakakibara S., Riley D.J., and Berg R.A. Chemotactic activity of collagen-like polypeptides for human peripheral blood neutrophils. J Leukoc Biol 39 3 (1986) 255-266
90. Lee K.S., Jin S.M., Kim S.S., and Lee Y.C. Doxycycline reduces airway inflammation and hyperresponsiveness in a murine model of toluene diisocyanate-induced asthma. J Allergy Clin Immunol 113 5 (2004) 902-909
91. Li Y.Y., and Feldman A.M. Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications. Drugs 61 9 (2001) 1239-1252
92. Luisetti M., Sturani C., Sella D., Madonini E., Galavotti V., Bruno G., et al. Mr889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial. Eur Respir J 9 7 (1996) 1482-1486
93. Luscombe M. Acid phosphatase and catheptic activity in rheumatoid synovial tissue. Nature 197 (1963) 1010
94. Maes M., Goossens F., Lin A., De Meester I., Van Gastel A., and Scharpe S. Effects of psychological stress on serum prolyl endopeptidase and dipeptidyl peptidase iv activity in humans: higher serum prolyl endopeptidase activity is related to stress-induced anxiety. Psychoneuroendocrinology 23 5 (1998) 485-495
95. Maes M., Goossens F., Scharpe S., Calabrese J., Desnyder R., and Meltzer H.Y. Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs. Psychiatry Res 58 3 (1995) 217-225
96. Maes M., Libbrecht I., Van Hunsel F., Lin A.H., Bonaccorso S., Goossens F., et al. Lower serum activity of prolyl endopeptidase in fibromyalgia is related to severity of depressive symptoms and pressure hyperalgesia. Psychol Med 28 4 (1998) 957-965
97. Maes M., Monteleone P., Bencivenga R., Goossens F., Maj M., van West D., et al. Lower serum activity of prolyl endopeptidase in anorexia and bulimia nervosa. Psychoneuroendocrinology 26 1 (2001) 17-26
98. Mahler D.A., Huang S., Tabrizi M., and Bell G.M. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest 126 3 (2004) 926-934
99. Malik M., Bakshi C.S., McCabe K., Catlett S.V., Shah A., Singh R., et al. Matrix metalloproteinase 9 activity enhances host susceptibility to pulmonary infection with type A and B strains of Francisella tularensis. J Immunol 178 2 (2007) 1013-1020
100. Marighetto A., Touzani K., Etchamendy N., Torrea C.C., De Nanteuil G., Guez D., et al. Further evidence for a dissociation between different forms of mnemonic expressions in a mouse model of age-related cognitive decline: effects of tacrine and S 17092, a novel prolyl endopeptidase inhibitor. Learn Mem 7 3 (2000) 159-169
101. Massova I., Kotra L.P., Fridman R., and Mobashery S. Matrix metalloproteinases: structures, evolution, and diversification. Faseb J 12 12 (1998) 1075-1095
102. Minematsu N., Nakamura H., Tateno H., Nakajima T., and Yamaguchi K. Genetic polymorphism in matrix metalloproteinase-9 and pulmonary emphysema. Biochem Biophys Res Commun 289 1 (2001) 116-119
103. Miravitlles M., Murio C., Guerrero T., and Gisbert R. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 123 3 (2003) 784-791
104. Molet S., Belleguic C., Lena H., Germain N., Bertrand C.P., Shapiro S.D., et al. Increase in macrophage elastase (MMP-12) in lungs from patients with chronic obstructive pulmonary disease. Inflamm Res 54 1 (2005) 31-36
105. Morain P., Boeijinga P.H., Demazieres A., De Nanteuil G., and Luthringer R. Psychotropic profile of S 17092, a prolyl endopeptidase inhibitor, using quantitative EEG in young healthy volunteers. Neuropsychobiology 55 3-4 (2007) 176-183
106. Morain P., Lestage P., De Nanteuil G., Jochemsen R., Robin J.L., Guez D., et al. S 17092: a prolyl endopeptidase inhibitor as a potential therapeutic drug for memory impairment. Preclinical and clinical studies. CNS Drug Rev 8 1 (2002) 31-52
107. Morain P., Robin J.L., De Nanteuil G., Jochemsen R., Heidet V., and Guez D. Pharmacodynamic and pharmacokinetic profile of S 17092, a new orally active prolyl endopeptidase inhibitor, in elderly healthy volunteers. A phase I study. Br J Clin Pharmacol 50 4 (2000) 350-359
108. Mydel P., Shipley J.M., Adair-Kirk T.L., Kelley D.G., Broekelmann T.J., Mecham R.P., et al. Neutrophil elastase cleavesllaminin-332 (laminin-5) generating peptides that are chemotactic for neutrophils. J Biol Chem 283 15 (2008) 9513-9522
109. Nenan S., Lagente V., Planquois J.M., Hitier S., Berna P., Bertrand C.P., et al. Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol 559 1 (2007) 75-81
110. Norris D.A., Clark R.A., Swigart L.M., Huff J.C., Weston W.L., and Howell S.E. Fibronectin fragment(s) are chemotactic for human peripheral blood monocytes. J Immunol 129 4 (1982) 1612-1618
111. O'Leary R.M., Gallagher S.P., and O'Connor B. Purification and characterization of a novel membrane-bound form of prolyl endopeptidase from bovine brain. Int J Biochem Cell Biol 28 4 (1996) 441-449
112. O'Leary R.M., and O'Connor B. Identification and localisation of a synaptosomal membrane prolyl endopeptidase from bovine brain. Eur J Biochem 227 1-2 (1995) 277-283
113. Ohbayashi H. Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs 11 7 (2002) 965-980
114. Ohnishi K., Takagi M., Kurokawa Y., Satomi S., and Konttinen Y.T. Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab Invest 78 9 (1998) 1077-1087
115. Oliveira E.B., Martins A.R., and Camargo A.C. Isolation of brain endopeptidases: Influence of size and sequence of substrates structurally related to bradykinin. Biochemistry 15 9 (1976) 1967-1974
116. Orlowski M., Wilk E., Pearce S., and Wilk S. Purification and properties of a prolyl endopeptidase from rabbit brain. J Neurochem 33 2 (1979) 461-469
117. Overall C.M., and Kleifeld O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer 94 7 (2006) 941-946
118. Pardo A., and Selman M. MMP-1: the elder of the family. Int J Biochem Cell Biol 37 2 (2005) 283-288
119. Pavlaki M., and Zucker S. Matrix metalloproteinase inhibitors (MMPIS): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 22 2-3 (2003) 177-203
120. Pemberton P.A., Cantwell J.S., Kim K.M., Sundin D.J., Kobayashi D., Fink J.B., et al. An inhaled matrix metalloprotease inhibitor prevents cigarette smoke-induced emphysema in the mouse. Copd 2 3 (2005) 303-310
121. Pemberton P.A., Kobayashi D., Wilk B.J., Henstrand J.M., Shapiro S.D., and Barr P.J. Inhaled recombinant alpha 1-antitrypsin ameliorates cigarette smoke-induced emphysema in the mouse. Copd 3 2 (2006) 101-108
122. Pfister R.R., Haddox J.L., and Lam K.W. Alkali-degraded cells generate a respiratory burst stimulant for neutrophils. Cornea 12 2 (1993) 155-160
123. Pfister R.R., Haddox J.L., Lam K.W., and Lank K.M. Preliminary characterization of a polymorphonuclear leukocyte stimulant isolated from alkali-treated collagen. Invest Ophthalmol Vis Sci 29 6 (1988) 955-962
124. Pfister R.R., Haddox J.L., and Sommers C.I. Alkali-degraded cornea generates a low molecular weight chemoattractant for polymorphonuclear leukocytes. Invest Ophthalmol Vis Sci 34 7 (1993) 2297-2304
125. Pfister R.R., Haddox J.L., and Sommers C.I. Injection of chemoattractants into normal cornea: a model of inflammation after alkali injury. Invest Ophthalmol Vis Sci 39 9 (1998) 1744-1750
126. Pfister R.R., Haddox J.L., Sommers C.I., and Lam K.W. Identification and synthesis of chemotactic tripeptides from alkali-degraded whole cornea. A study of n-acetyl-proline-glycine-proline and n-methyl-proline-glycine-proline. Invest Ophthalmol Vis Sci 36 7 (1995) 1306-1316
127. Pharmaceuticals O. Announcement of the Suspension of Clinical Study in Japan Using ONO-6818 for Chronic Obstructive Pulmonary Disease: BUSINESS WIRE (2002)
128. Pharmaceuticals O. Announcement of Termination of Exclusive License Agreement on Sivelestat with Lilly Corporation (2003)
129. Polgar L. The prolyl oligopeptidase family. Cell Mol Life Sci 59 2 (2002) 349-362
130. Postlethwaite A.E., and Kang A.H. Collagen- and collagen peptide-induced chemotaxis of human blood monocytes. J Exp Med 143 6 (1976) 1299-1307
131. Postlethwaite A.E., Seyer J.M., and Kang A.H. Chemotactic attraction of human fibroblasts to type I, II, and III collagens and collagen-derived peptides. Proc Natl Acad Sci U S A 75 2 (1978) 871-875
132. Privitera S., Prody C.A., Callahan J.W., and Hinek A. The 67-kDa enzymatically inactive alternatively spliced variant of beta-galactosidase is identical to the elastin/laminin-binding protein. J Biol Chem 273 11 (1998) 6319-6326
133. Rao N.V., Marshall B.C., Gray B.H., and Hoidal J.R. Interaction of secretory leukocyte protease inhibitor with proteinase-3. Am J Respir Cell Mol Biol 8 6 (1993) 612-616
134. Rao N.V., Wehner N.G., Marshall B.C., Gray W.R., Gray B.H., and Hoidal J.R. Characterization of proteinase-3 (PR-3), a neutrophil serine proteinase. Structural and functional properties. J Biol Chem 266 15 (1991) 9540-9548
135. Riley D.J., Berg R.A., Soltys R.A., Kerr J.S., Guss H.N., Curran S.F., et al. Neutrophil response following intratracheal instillation of collagen peptides into rat lungs. Exp Lung Res 14 4 (1988) 549-563
136. Riley D.J., Kerr J.S., Guss H.N., Curran S.F., Laskin D.L., and Berg R.A. Intratracheal instillation of collagen peptides induces a neutrophil influx in rat lungs. Trans Assoc Am Physicians 97 (1984) 290-295
137. Rosenblum J.S., and Kozarich J.W. Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr Opin Chem Biol 7 4 (2003) 496-504
138. Rubin B.K., Druce H., Ramirez O.E., and Palmer R. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Am J Respir Crit Care Med 155 6 (1997) 2018-2023
139. Schneider J.S., Giardiniere M., and Morain P. Effects of the prolyl endopeptidase inhibitor S 17092 on cognitive deficits in chronic low dose MPTP-treated monkeys. Neuropsychopharmacology 26 2 (2002) 176-182
140. Segura-Valdez L., Pardo A., Gaxiola M., Uhal B.D., Becerril C., and Selman M. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest 117 3 (2000) 684-694
141. Selman M., Cisneros-Lira J., Gaxiola M., Ramirez R., Kudlacz E.M., Mitchell P.G., et al. Matrix metalloproteinases inhibition attenuates tobacco smoke-induced emphysema in guinea pigs. Chest 123 5 (2003) 1633-1641
142. Selman M., Montano M., Ramos C., Vanda B., Becerril C., Delgado J., et al. Tobacco smoke-induced lung emphysema in guinea pigs is associated with increased interstitial collagenase. Am J Physiol 271 5 Pt 1 (1996) L734-743
143. Senior R.M., Griffin G.L., and Mecham R.P. Chemotactic activity of elastin-derived peptides. J Clin Invest 66 4 (1980) 859-862
144. Senior R.M., Griffin G.L., Mecham R.P., Wrenn D.S., Prasad K.U., and Urry D.W. Val-Gly-Val-Ala-Pro-Gly, a repeating peptide in elastin, is chemotactic for fibroblasts and monocytes. J Cell Biol 99 3 (1984) 870-874
145. Senior R.M., Hinek A., Griffin G.L., Pipoly D.J., Crouch E.C., and Mecham R.P. Neutrophils show chemotaxis to type IV collagen and its 7S domain and contain a 67 kD type IV collagen binding protein with lectin properties. Am J Respir Cell Mol Biol 1 6 (1989) 479-487
146. Senior R.M., Tegner H., Kuhn C., Ohlsson K., Starcher B.C., and Pierce J.A. The induction of pulmonary emphysema with human leukocyte elastase. Am Rev Respir Dis 116 3 (1977) 469-475
147. Sepper R., Konttinen Y.T., Sorsa T., and Koski H. Gelatinolytic and type IV collagenolytic activity in bronchiectasis. Chest 106 4 (1994) 1129-1133
148. Shapiro S.D., Goldstein N.M., Houghton A.M., Kobayashi D.K., Kelley D., and Belaaouaj A. Neutrophil elastase contributes to cigarette smoke-induced emphysema in mice. Am J Pathol 163 6 (2003) 2329-2335
149. Shapiro S.D., and Senior R.M. Matrix metalloproteinases. Matrix degradation and more. Am J Respir Cell Mol Biol 20 6 (1999) 1100-1102
150. Shimane T., Asano K., Suzuki M., Hisamitsu T., and Suzaki H. Influence of a macrolide antibiotic, roxithromycin, on mast cell growth and activation in vitro. Mediators Inflamm 10 6 (2001) 323-332
151. Shirasawa Y., Osawa T., and Hirashima A. Molecular cloning and characterization of prolyl endopeptidase from human T cells. J Biochem 115 4 (1994) 724-729
152. Smith C., and Hamerman D. Aic phosphatase in human synovial fluid. Arthritis Rheum 5 (1962) 11-14
153. Solomon A., Rosenblatt M., Li D., Monroy D., Ji Z., Lokeshwar B.L., et al. Doxycycline inhibition of interleukin-1 in the corneal epithelium. Am J Ophthalmol 130 5 (2000) 688
154. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 200 4 (2003) 448-464
155. Sternlicht M.D., and Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17 (2001) 463-516
156. Steward W.P. Marimastat (BB2516): current status of development. Cancer Chemother Pharmacol 43 Suppl (1999) S56-60
157. Stoller J.K., and Aboussouan L.S. Alpha1-antitrypsin deficiency. Lancet 365 9478 (2005) 2225-2236
158. Suomalainen K., Sorsa T., Golub L.M., Ramamurthy N., Lee H.M., Uitto V.J., et al. Specificity of the anticollagenase action of tetracyclines: relevance to their anti-inflammatory potential. Antimicrob Agents Chemother 36 1 (1992) 227-229
159. Sutherland E.R., and Cherniack R.M. Management of chronic obstructive pulmonary disease. N Engl J Med 350 26 (2004) 2689-2697
160. Takizawa H., Desaki M., Ohtoshi T., Kawasaki S., Kohyama T., Sato M., et al. Erythromycin modulates il-8 expression in normal and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med 156 1 (1997) 266-271
161. Toide K., Fujiwara T., Iwamoto Y., Shinoda M., Okamiya K., and Kato T. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on neuropeptide metabolism in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 353 3 (1996) 355-362
162. Toide K., Iwamoto Y., Fujiwara T., and Abe H. JTP-4819: a novel prolyl endopeptidase inhibitor with potential as a cognitive enhancer. J Pharmacol Exp Ther 274 3 (1995) 1370-1378
163. Toide K., Okamiya K., Iwamoto Y., and Kato T. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on prolyl endopeptidase activity and substance p- and arginine-vasopressin-like immunoreactivity in the brains of aged rats. J Neurochem 65 1 (1995) 234-240
164. Toide K., Shinoda M., Fujiwara T., and Iwamoto Y. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on spatial memory and central cholinergic neurons in aged rats. Pharmacol Biochem Behav 56 3 (1997) 427-434
165. Toide K., Shinoda M., Iwamoto Y., Fujiwara T., Okamiya K., and Uemura A. A novel prolyl endopeptidase inhibitor, JTP-4819, with potential for treating Alzheimer's disease. Behav Brain Res 83 1-2 (1997) 147-151
166. Toide K., Shinoda M., and Miyazaki A. A novel prolyl endopeptidase inhibitor, JTP-4819-its behavioral and neurochemical properties for the treatment of Alzheimer's disease. Rev Neurosci 9 1 (1998) 17-29
167. Trifilieff A. ONO-6818 Cortech/Ono. Curr Opin Investig Drugs 3 8 (2002) 1161-1164
168. Tsang K.W., Ho P.I., Chan K.N., Ip M.S., Lam W.K., Ho C.S., et al. A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J 13 2 (1999) 361-364
169. Van den Steen P.E., Dubois B., Nelissen I., Rudd P.M., Dwek R.A., and Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 37 6 (2002) 375-536
170. Van den Steen P.E., Proost P., Wuyts A., Van Damme J., and Opdenakker G. Neutrophil gelatinase b potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 96 8 (2000) 2673-2681
171. van Houwelingen A.H., Weathington N.M., Verweij V., Blalock J.E., Nijkamp F.P., and Folkerts G. Induction of lung emphysema is prevented by l-arginine-threonine-arginine. FASEB J 22 9 (2008) 3403-3408
172. Van Lint P., and Libert C. Matrix metalloproteinase-8: cleavage can be decisive. Cytokine Growth Factor Rev 17 4 (2006) 217-223
173. Vanhoof G., Goossens F., Hendriks L., De Meester I., Hendriks D., Vriend G., et al. Cloning and sequence analysis of the gene encoding human lymphocyte prolyl endopeptidase. Gene 149 2 (1994) 363-366
174. Venalainen J.I., Juvonen R.O., and Mannisto P.T. Evolutionary relationships of the prolyl oligopeptidase family enzymes. Eur J Biochem 271 13 (2004) 2705-2715
175. Vernooy J.H., Lindeman J.H., Jacobs J.A., Hanemaaijer R., and Wouters E.F. Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. Chest 126 6 (2004) 1802-1810
176. Villagrasa V., Berto L., Cortijo J., Perpina M., Sanz C., and Morcillo E.J. Effects of erythromycin on chemoattractant-activated human polymorphonuclear leukocytes. Gen Pharmacol 29 4 (1997) 605-609
177. Voet D., and Voet J. Biochemistry (2nd ed.) (1995), John Wiley and Sons, Inc, New York
178. Wallen E.A., Christiaans J.A., Jarho E.M., Forsberg M.M., Venalainen J.I., Mannisto P.T., et al. New prolyl oligopeptidase inhibitors developed from dicarboxylic acid bis(l-prolyl-pyrrolidine) amides. J Med Chem 46 21 (2003) 4543-4551
179. Walsh D.E., Greene C.M., Carroll T.P., Taggart C.C., Gallagher P.M., O'Neill S.J., et al. Interleukin-8 up-regulation by neutrophil elastase is mediated by MyD88/IRAK/TRAF-6 in human bronchial epithelium. J Biol Chem 276 38 (2001) 35494-35499
180. Walter R. Partial purification and characterization of post-proline cleaving enzyme: enzymatic inactivation of neurohypophyseal hormones by kidney preparations of various species. Biochim Biophys Acta 422 1 (1976) 138-158
181. Walter R., Shlank H., Glass J.D., Schwartz I.L., and Kerenyi T.D. Leucylglycinamide released from oxytocin by human uterine enzyme. Science 173 999 (1971) 827-829
182. Weathington N.M., van Houwelingen A.H., Noerager B.D., Jackson P.L., Kraneveld A.D., Galin F.S., et al. A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nat Med 12 3 (2006) 317-323
183. Weissmann G. Lysosomal mechanisms of tissue injury in arthritis. N Engl J Med 286 3 (1972) 141-147
184. Weissmann G., and Spilberg I. Breakdown of cartilage proteinpolysaccharide by lysosomes. Arthritis Rheum 11 2 (1968) 162-169
185. Wilson R. Bacteria and airway inflammation in chronic obstructive pulmonary disease: more evidence. Am J Respir Crit Care Med 172 2 (2005) 147-148
186. Wright J.L., and Churg A. Smoke-induced emphysema in guinea pigs is associated with morphometric evidence of collagen breakdown and repair. Am J Physiol 268 1 Pt 1 (1995) L17-20
187. Yoshimoto T., Kado K., Matsubara F., Koriyama N., Kaneto H., and Tsura D. Specific inhibitors for prolyl endopeptidase and their anti-amnesic effect. J Pharmacobiodyn 10 12 (1987) 730-735
188. Yoshimoto T., Ogita K., Walter R., Koida M., and Tsuru D. Post-proline cleaving enzyme. Synthesis of a new fluorogenic substrate and distribution of the endopeptidase in rat tissues and body fluids of man. Biochim Biophys Acta 569 2 (1979) 184-192
189. Yoshioka A., Betsuyaku T., Nishimura M., Miyamoto K., Kondo T., and Kawakami Y. Excessive neutrophil elastase in bronchoalveolar lavage fluid in subclinical emphysema. Am J Respir Crit Care Med 152 6 Pt 1 (1995) 2127-2132
190. Zeiher B.G., Artigas A., Vincent J.L., Dmitrienko A., Jackson K., Thompson B.T., et al. Neutrophil elastase inhibition in acute lung injury: results of the strive study. Crit Care Med 32 8 (2004) 1695-1702
191. Zheng T., Zhu Z., Wang Z., Homer R.J., Ma B., Riese Jr. R.J., et al. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J Clin Invest 106 9 (2000) 1081-1093
192. Zolfaghari R., Baker C.R., Canizaro P.C., Feola M., Amirgholami A., and Behal F.J. Human lung post-proline endopeptidase: purification and action on vasoactive peptides. Enzyme 36 3 (1986) 165-178